Processa Pharmaceuticals (PCSA) has released an update to notify the public and investors about a regulation fd disclosure.
Processa Pharmaceuticals, Inc. announced the expansion of its NGC-Cap program to include advanced or metastatic breast cancer and noted that the FDA has allowed the use of existing data and studies to support the design of a Phase 2 breast cancer trial. The details of this announcement are not considered filed under the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filings, except as explicitly stated.
For further insights into PCSA stock, check out TipRanks’ Stock Analysis page.
